Valuation: Exact Sciences Corporation

Market Cap 20.03B 17.46B 16.45B 14.98B 28.08B 1,919B 28.11B 197B 75.91B 977B 75.22B 73.56B 3,154B P/E 2024
-10.1x
P/E 2025 -92.2x
Enterprise Value 21.6B 18.83B 17.73B 16.15B 30.28B 2,069B 30.32B 212B 81.86B 1,054B 81.12B 79.32B 3,401B EV / Sales 2024
4.4x
EV / Sales 2025 6.42x
Free-Float
98.24%
Yield 2024 *
-
Yield 2025 -
1 day+0.95%
Current year+3.30%
Current year 101.51
Extreme 101.51
104.98
1 year 51.75
Extreme 51.75
104.98
3 years 38.81
Extreme 38.8118
104.98
5 years 29.27
Extreme 29.27
104.98
10 years 13.05
Extreme 13.05
159.54
Date Insider Type Main position Quantity % Market Cap. Importance
3/23/26 Issuer sale

Director

28,899 0.0151%
3/23/26 Free

Executive/Senior Manager

199,374 0.1044%
3/23/26 Issuer sale

Director

20,558 0.0108%
Change 5-day change 1-year change 3-year change Capi.($)
+0.95%-.--%+96.76%+50.88% 20.03B
-0.59%+10.04%+397.07%+102.38% 4.64B
-2.62%+12.43%+108.53%+437.84% 4.57B
+4.33%+0.75%+21.72%+83.72% 3.2B
+0.93%+3.74%+272.38%+601.03% 2.78B
+6.75%+15.41%-16.39%-19.04% 2.27B
-2.98%+10.96%+56.60% - 1.84B
+0.89%+6.73%+28.20%+62.00% 1.11B
+2.87%+7.26%+165.56%-28.59% 1.04B
+5.23%+1.37%-15.35%+65.52% 568M
Average +1.58%+7.34%+111.51%+150.64% 4.2B
Weighted average by Cap. +0.89%+5.17%+127.62%+136.00%

Financials

2024 2025
Net sales 2.76B 2.41B 2.27B 2.06B 3.87B 264B 3.87B 27.13B 10.46B 135B 10.36B 10.13B 434B 3.25B 2.83B 2.67B 2.43B 4.55B 311B 4.56B 31.93B 12.31B 158B 12.2B 11.93B 511B
Net income -1.03B -897M -845M -769M -1.44B -98.57B -1.44B -10.12B -3.9B -50.21B -3.86B -3.78B -162B -208M -181M -171M -156M -292M -19.92B -292M -2.05B -788M -10.15B -781M -764M -32.75B
Net Debt 1.74B 1.52B 1.43B 1.3B 2.44B 166B 2.44B 17.09B 6.59B 84.8B 6.53B 6.38B 274B 1.57B 1.37B 1.29B 1.17B 2.2B 150B 2.2B 15.44B 5.95B 76.62B 5.9B 5.77B 247B
Logo Exact Sciences Corporation
Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. It offers a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. Its portfolio includes brands such as Cologuard and Oncotype DX, along with solutions like Cancerguard for blood-based analysis of molecular information across multiple cancers and Oncodetect for molecular residual disease and recurrence monitoring. Its flagship screening products, the Cologuard and Cologuard Plus tests, are patient-friendly, non-invasive, stool-based DNA (sDNA) screening tests that utilize a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Its Cancerguard test is designed to detect multiple cancers in their earliest stages from a single blood draw. It offers predefined genetic tests for all clinically relevant genes, and whole genome (PGnome) sequencing tests.
Employees
7,150
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
AAA
  1. Stock Market
  2. Stocks
  3. EXAS Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!